LEADER 01481nas 2200493- 450 001 996203799403316 005 20221226230518.0 035 $a(OCoLC)622395969 035 $a(CKB)958480159186 035 $a(CONSER)--2016207201 035 $a(DE-599)ZDB2405693-5 035 $a(EXLCZ)99958480159186 100 $a20100519a20uu9999 --- - 101 0 $aeng 135 $aurbn||||||abp 135 $aurbn||||||ada 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aTatra Mountains mathematical publications 210 1$aBratislava :$cMathematical Institute, Slovak Academy of Sciences 210 31$aWarsaw, Poland :$cDE GRUYTER OPEN 215 $avolumes ;$d24 cm 300 $aRefereed/Peer-reviewed 300 $aRefereed/Peer-reviewed 300 $aEach issue has also distinctive title. 311 $a1210-3195 517 3 $aTatra Mountains 517 1 $aJournal of Slovak Academy of Sciences 531 $aTATRA MT. MATH. PUBL 606 $aMathematics$vPeriodicals 606 $aMathematics$2fast$3(OCoLC)fst01012163 606 $aWiskunde$2gtt 608 $aPeriodicals.$2fast 615 0$aMathematics 615 7$aMathematics. 615 17$aWiskunde. 676 $a510 712 02$aSlovenská akadémia vied. 712 02$aMatematický ústav SAV. 906 $aJOURNAL 912 $a996203799403316 996 $aTatra Mountains mathematical publications$9256867 997 $aUNISA LEADER 06579nam 22006855 450 001 9910298325703321 005 20251116133911.0 010 $a1-4939-1289-5 024 7 $a10.1007/978-1-4939-1289-6 035 $a(CKB)3710000000343577 035 $a(EBL)1969289 035 $a(SSID)ssj0001424629 035 $a(PQKBManifestationID)11784578 035 $a(PQKBTitleCode)TC0001424629 035 $a(PQKBWorkID)11383640 035 $a(PQKB)10260463 035 $a(MiAaPQ)EBC1969289 035 $a(DE-He213)978-1-4939-1289-6 035 $a(PPN)183516486 035 $a(EXLCZ)993710000000343577 100 $a20150130d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aTopical Drug Bioavailability, Bioequivalence, and Penetration /$fedited by Vinod P. Shah, Howard I. Maibach, John Jenner 205 $a2nd ed. 2014. 210 1$aNew York, NY :$cSpringer New York :$cImprint: Springer,$d2014. 215 $a1 online resource (393 p.) 300 $aDescription based upon print version of record. 311 08$a1-4939-1288-7 320 $aIncludes bibliographical references and index. 327 $a1 Percutaneous Absorption -- 2 Animal Models for Percutaneous Absorption -- 3 Mitigating Dermal Exposure to Agrochemicals -- 4 Importance of In Vitro Drug Release -- 5 Diffusion Cell Design -- 6 In Vitro Product Quality Tests and Product Performance Tests for Topical and Transdermal Drug Products -- 7 Safety and efficacy testing of topical products; Practical considerations -- 8 Challenges in Evaluating Bioequivalence of Topical Dermatological Drug Products -- 9 Methods for the Assessment of Bioequivalence of Topical Dosage Forms: Correlations, Optimization Strategies and Innovative Approaches -- 10 Application of Microdialysis in Assessing Cutaneous Bioavailability -- 11 Follicular Drug Penetration -- 12 Development of Pilosebaceous Unit-Targeted Drug Products -- 13 Deep Percutaneous Penetration into Muscles and Joints: Update -- 14 Efficacy & Toxicity of Microneedle based devices -- 15 Mathematical Models for Topical and Transdermal Drug Products -- 16 Transdermal Patches: An Industrial Perspective on the Relevance of in vitro Skin Permeation Studies and Approaches on Design of Manufacturing Processes -- 17 Transdermal Drug Delivery Systems.  Regulatory Considerations:  NDA and ANDA Requirements -- 18 Transdermal Estradiol and Testosterone Transfer in Man: Existence, Models, and Strategies for Prevention -- 19 Effects of occlusion on dermal drug delivery: implications for bioequivalence measurement -- 20 Challenges with Clinical Endpoints ? Bioequivalence -- 21 Clinical Considerations of Bioequivalence For Topical Dermatologic Drugs -- 22 OECD Test Guideline 428 ? A method for in vitro percutaneous absorption measurement? -- 23 Bioequivalence, Quality, and Novel Assessment Technologies for Topical Products: Current Challenges and Future Prospects. 330 $aThis authoritative volume explores advances in the techniques used to measure percutaneous penetration of drugs and chemicals to assess bioavailability and bioequivalence and discusses how they have been used in clinical and scientific investigations. Seven comprehensive sections examine topics including in vitro drug release, topical drugs products, clinical studies, and guidelines and workshop reports, among others. The book also describes how targeted transdermal drug delivery and more sophisticated mathematical modeling can aid in understanding the bioavailability of transdermal drugs. The first edition of this book was an important reference guide for researchers working to define the effectiveness and safety of drugs and chemicals that penetrated the skin. This second edition contains cutting-edge advances in the field and is a key resource to those seeking to define the bioavailability and bioequivalence of percutaneously active compounds to improve scientific and clinical investigation and regulation.   Vinod P. Shah is a pharmaceutical consultant. He was Scientific Secretary of the International Pharmaceutical Federation (FIP) and is now Chair of the FIP Regulatory Sciences Special Interest Group. Dr. Shah has served at the U.S. Food and Drug Administration and has developed several regulatory guidances for the pharmaceutical industry in biopharmaceutics and topical drug products. Howard I. Maibach is professor of dermatology at the University of California, San Francisco. He received his M.D. at Tulane University Medical School in New Orleans, Louisiana, and completed his residency and research fellowships at the University of Pennsylvania in Philadelphia, Pennsylvania. Professor Maibach is a leading authority in the fields of dermatotoxicology and dermatopharmacology, in which he has conducted research and written extensively. John Jenner is a principal scientist at The Defence Science and Technology Laboratory in the UK. He has a degree in pharmacology from the University of Manchester in Manchester, UK, and a Ph.D. from the University of Surrey, Guildford, UK. John has spent his career studying defense against and treatment of highly toxic chemicals. He has an enduring research interest in percutaneously active chemicals, whether toxic materials or drugs, and experience in the design and testing of transdermal formulations. 606 $aPharmacology 606 $aPhysiology 606 $aBiophysics 606 $aBiophysics 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aAnimal Physiology$3https://scigraph.springernature.com/ontologies/product-market-codes/L33030 606 $aBiological and Medical Physics, Biophysics$3https://scigraph.springernature.com/ontologies/product-market-codes/P27008 615 0$aPharmacology. 615 0$aPhysiology. 615 0$aBiophysics. 615 0$aBiophysics. 615 14$aPharmacology/Toxicology. 615 24$aAnimal Physiology. 615 24$aBiological and Medical Physics, Biophysics. 676 $a571.1 676 $a571.4 676 $a610 676 $a615 702 $aShah$b Vinod P.$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aMaibach$b Howard I.$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aJenner$b John$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910298325703321 996 $aTopical Drug Bioavailability, Bioequivalence, and Penetration$92537242 997 $aUNINA